171.45 +0.17 (0.10%)
After hours: 7:18PM EDT
|Bid||171.45 x 800|
|Ask||171.45 x 1300|
|Day's Range||171.09 - 173.77|
|52 Week Range||166.30 - 210.19|
|Beta (3Y Monthly)||0.90|
|PE Ratio (TTM)||13.66|
|Forward Dividend & Yield||5.80 (3.23%)|
|1y Target Est||N/A|
Biotech has held up better than some other areas of the health-care sector this year, although the industry has still mostly lagged the broader market. Citigroup says it is time to buy.
Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.
Amgen announced Wednesday an agreement to buy Copenhagen-based Nuevolution for $167 million. The U.S. company announced a recommended public cash offer to Nuevolution shareholders to tender their shares for 32.5 Swedish kronas ($3.37) each in cash. The target company's board has unanimously recommended Amgen's cash tender offer to its shareholders.
Amgen, the world's largest biotechnology company, said on Wednesday it offered to buy Scandinavian biopharmaceutical company Nuevolution AB for 1.61 billion Swedish crowns . Amgen's cash offer of 32.5 ...
It's been a rather green day on Wall Street as all three major indexes are positive. The Dow Jones is up over 150 points while the S&P 500 is up 0.84%. Among the stocks traders are watching include Apple Inc. (NASDAQ:AAPL), Biogen Inc. (NASDAQ:BIIB), Amgen, Inc. (NASDAQ:AMGN), Deckers Outdoor Corp (NASDAQ:DECK), and Diamondback Energy Inc (NASDAQ:FANG). Let's analyze why each stock is […]
Medicines Company announced interim results Saturday from the ongoing Phase 2 ORION-3 study that is evaluating the efficacy, safety and tolerability of inclisiran 300 mg in patients with atherosclerotic cardiovascular disease and elevated LDL cholesterol. The results show a consistent lowering of LDL cholesterol by more than 50 percent, with an overall follow-up of up to three years. The results were presented as a late-breaking presentation at the National Lipid Association Scientific Sessions in Miami.
Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.
Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.
Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares were rallying by about 15 percent Thursday as traders circulated word that drugmaker Amgen, Inc. (NASDAQ: AMGN ) KRAS G12C inhibitor abstract showed promising ...
The drug development pipelines of Gilead Sciences, Amgen and Biogen are running thin, and the companies might need to M&A to get going again, according to JPMorgan.
With rapid growth projected for the market for wearable drug delivery devices, investors would be wise to consider some of the key players in the business. Two standouts are Boston-area-based Insulet (PODD) and West Pharmaceutical Services (WST), which is headquartered in Exton, Pennsylvania. Warning! GuruFocus has detected 4 Warning Signs with PODD.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 14) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Avedro Inc ...
AbbVie (ABBV) resolves its litigation with Boehringer Ingelheim over U.S. patents for its blockbuster rheumatoid arthritis drug, Humira.
Lilly's (LLY) Cyramza gets FDA approval to treat AFP-high hepatocellular carcinoma (HCC), a common form of liver cancer. FDA removes boxed warning from label.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of first-time patients at 37.7 percent, for the first time outstripping Amgen’s Aimovig, whose share dropped to 37.2 percent as of April 26. Teva came in at a 25.1 percent share, according to an analyst who reviewed the data.